Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloid leukemia.

Richard T Silver1

  • 1Weill Cornell Medical College, 525 East 68th Street, Box 581, New York, NY 10021, USA. rtsilve@med.cornell.edu

Hematology/Oncology Clinics of North America
|October 17, 2003
PubMed
Summary

Chronic myeloid leukemia (CML) is a stem cell disorder characterized by the Philadelphia chromosome. This review covers CML

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.

Leukemia·2026
Same author

Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera.

Leukemia research·2025
Same author

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.

Blood neoplasia·2025
Same author

Automated Information Extraction from Unstructured Hematopathology Reports to Support Response Assessment in Myeloproliferative Neoplasms.

Methods of information in medicine·2025
Same author

DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera.

Blood·2025
Same author

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).

Transplantation and cellular therapy·2024

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder originating from a pluripotent stem cell.
  • A hallmark of CML is the Philadelphia chromosome, a specific cytogenetic abnormality.
  • CML affects myeloid, erythroid, megakaryocytic, and lymphoid cells, but not marrow fibroblasts.

Purpose of the Study:

  • To review the hematologic and clinical aspects of chronic myeloid leukemia.
  • To discuss advances in understanding the cytogenetics and molecular biology of CML.
  • To review current and emerging treatment strategies for CML.

Main Methods:

  • Review of scientific literature on CML.
  • Analysis of hematologic and clinical data.
  • Discussion of cytogenetic and molecular biology findings.
  • Evaluation of treatment programs.

Main Results:

  • Significant advances in understanding CML's molecular basis and clinical presentation.
  • Established treatment regimens include busulfan, hydroxyurea, interferon, and marrow transplantation.
  • Imatinib mesylate represents a new paradigm in cancer chemotherapy for CML.

Conclusions:

  • CML is a well-defined disease with significant molecular and genetic underpinnings.
  • Conventional therapies remain relevant, but imatinib mesylate offers a novel therapeutic approach.
  • Continued research in CML biology and treatment is crucial.

Related Experiment Videos